EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Pharmacologic de-escalation of dexamethasone during weekly paclitaxel: a randomized phase III trial evaluating safety, endocrine effects, and quality of life

Vanessa Armenio Scontre, Marcos Tadashi Kakitani Toyoshima, Maria Del Pilar Estevez-Diz

Cancer Chemotherapy and Pharmacology · 13.07.2026 · 96 (1)

DOI: 10.1007/s00280-026-04920-x ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 13.07.2026. Verfasst von Vanessa Armenio Scontre und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Oncology, Instituto do Cancer do Estado de Sao Paulo - Faculdade de Medicina da Universidade de Sao Paulo, Avenida Dr. Ar…. Hauptthemen laut MEDLINE: Paclitaxel, Quality of Life, Breast Neoplasms, Dexamethasone. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade De São Paulo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Dexamethasone is routinely used as premedication during weekly paclitaxel to prevent hypersensitivity reactions; however, prolonged corticosteroid exposure may induce clinically relevant metabolic, endocrine, and patient-reported adverse effects. This study evaluated whether selective omission of dexamethasone after the second paclitaxel infusion is safe and explored its effects on quality of life, metabolic/endocrine parameters, and short-term oncologic outcomes, including recurrence and disease-related mortality.

Methods

In this prospective, randomized, open-label phase III trial, 86 women with stage I–III breast cancer receiving neoadjuvant or adjuvant AC-T or AC-TH chemotherapy were randomized 1:1 to standard dexamethasone premedication or omission after the second weekly paclitaxel infusion. The primary endpoint was safety, defined by hypersensitivity reactions and adverse events. Secondary and exploratory endpoints included patient-reported quality of life using the EORTC QLQ-C30, metabolic and endocrine parameters, and short-term oncologic outcomes. Longitudinal changes were analyzed using generalized estimating equations.

Results

Eighty-four patients were included in the final analysis. No hypersensitivity reactions occurred after dexamethasone omission, and treatment completion rates were comparable between groups. After a median follow-up of 3.15 years, recurrence and disease-related mortality were similar between groups in descriptive analyses. The omission strategy was associated with improvements in role functioning and reduced worsening of pain ( p = 0.02), constipation ( p = 0.01), and nausea/vomiting ( p = 0.03). No statistically significant differences were observed for emotional or physical functioning. Endocrine analyses demonstrated reduced IGF-1 levels and a trend toward lower insulin levels. These secondary analyses should be interpreted as exploratory.

Conclusion

Selective omission of dexamethasone after the second weekly paclitaxel infusion was safe and well tolerated in this randomized trial. The findings support the feasibility of a corticosteroid-sparing strategy during weekly paclitaxel and suggest potential benefits in selected patient-reported and endocrine outcomes, which warrant confirmation in larger studies.

Trial registration

NCT04350229, registered on 16 April 2020.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelQuality of LifeBreast NeoplasmsDexamethasoneHumansFemaleMiddle AgedProspective StudiesAgedAdultDrug Administration ScheduleNeoadjuvant Therapy

Stichwörter der Autor:innen

Breast cancerDexamethasoneEndocrine effectsPaclitaxelPremedicationSteroid-sparing

Substanzen

PaclitaxelDexamethasone

Autor:innen und Institutionen

  • Department of Radiology and Oncology, Instituto do Cancer do Estado de Sao Paulo - Faculdade de Medicina da Universidade de Sao Paulo, Avenida Dr. Arnaldo, 251 - 5º Andar, Sao Paulo, 01246-000, SP, Brazil. vanessa.scont…
  • Endocrine Oncology Service, Instituto do Cancer do Estado de Sao Paulo - Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Brazil.
  • Department of Radiology and Oncology, Instituto do Cancer do Estado de Sao Paulo - Faculdade de Medicina da Universidade de Sao Paulo, Avenida Dr. Arnaldo, 251 - 5º Andar, Sao Paulo, 01246-000, SP, Brazil.

Förderung

  • Universidade De São Paulo

Zitieren

APA

Scontre, V. A., Toyoshima, M. T. K., & Estevez-Diz, M. D. P. (2026). Pharmacologic de-escalation of dexamethasone during weekly paclitaxel: a randomized phase III trial evaluating safety, endocrine effects, and quality of life. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04920-x

Vancouver

Scontre VA, Toyoshima MTK, Estevez-Diz MDP. Pharmacologic de-escalation of dexamethasone during weekly paclitaxel: a randomized phase III trial evaluating safety, endocrine effects, and quality of life. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04920-x

BibTeX
@article{Scontre2026,
  author = {Scontre, Vanessa Armenio and Toyoshima, Marcos Tadashi Kakitani and Estevez-Diz, Maria Del Pilar},
  title = {Pharmacologic de-escalation of dexamethasone during weekly paclitaxel: a randomized phase III trial evaluating safety, endocrine effects, and quality of life},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  volume = {96},
  number = {1},
  doi = {10.1007/s00280-026-04920-x}
}
Kostenlos starten →